Idiopathic thrombocytopenic purpura (ITP) is a common disease in hematology. With the main manifestation of marked reduction of platelets and bleeding from skin mucosa and even organs, the current treatment is mostly based on immunosuppressive therapy. However, in clinical work we can often encounter this kind of patients, who must pursue platelets to raise to the level of normal people, this attitude is not desirable. The main function of platelets is to stop bleeding, and the main problem of ITP is also bleeding. We can easily understand, as long as the patient does not bleed will not be enough? Why must the platelets be raised to normal energy? Some patients may ask, if it can be raised to normal levels, why not? Herein lies the problem of inconsistent understanding between doctors and patients. Which perception is correct? Undoubtedly, the doctor is right. It is also wrong if some doctor must raise your platelets to normal levels and keep increasing the dose or applying drugs like prednisone and Medrol for a long time in high doses. It is understandable for a patient to ask for raising platelets to normal levels. However, we should recognize that for some patients, this may require an increased dose of prednisone or a higher dose for a long period of time to maintain, with the resulting side effects being unacceptable. Such as infections due to the patient’s reduced resistance, edema due to long-term corticosteroid application, the appearance of full moon faces and buffalo waists, facial acne, and even osteoporosis and femoral head necrosis, and all of these side effects are far more harmful than platelet reduction. This is typical of the dangers associated with overmedication. So what are the criteria for treating ITP and its efficacy? There should be 3 levels, first, normal platelets, which is the best; second, platelets can not reach the normal requirements, but can also maintain about 50,000, will not affect the patient’s quality of life, which is also acceptable; third, platelets are significantly low, in the 10,000 or so, may partially limit the patient’s life, such as can not engage in strenuous sports, etc.. This last point is often a nagging concern for patients. The problem is that such patients are generally taking 2-4 tablets of prednisone on a continuous basis. Increasing the dose may raise the platelets, but they do not realize that the resulting side effects are more harmful, and it is then the doctor’s responsibility to explain the situation to the patient and help prompt them to understand the purpose of the treatment, rather than accommodating the patient by raising the hormone dose indefinitely to achieve the purpose of raising the platelets. The American Society of Hematology, the British Hematology Society Standardization Committee, and the Chinese Expert Consensus on ITP treatment all clearly mention that the minimum treatment goal for ITP is no bleeding, not long-term high-dose hormone application. This is something that I hope patients will fully realize and understand, and recognize the dangers of overmedication.